PodParley PodParley
PodParley
MPR Weekly Dose Podcast #281 — Kalshi Start Clinical Trial Predictions; Positive Results for Retatrutide; Jideytro Approved; Smart Toilet Launches; Daraxonrasib NDA Accepted episode artwork

EPISODE · Jul 24, 2026 · 15 MIN

MPR Weekly Dose Podcast #281 — Kalshi Start Clinical Trial Predictions; Positive Results for Retatrutide; Jideytro Approved; Smart Toilet Launches; Daraxonrasib NDA Accepted

from MPR Weekly Dose

Kalshi start clinical trials, FDA approvals prediction market; positive results shared for triple hormone therapy retatrutide; Jideytro gains approval in advanced or metastatic ROS1-positive NSCLC; a smart toilet seat hits the market to measure your vitals; and the FDA accepts an application for pretreated metastatic pancreatic cancer treatment, daraxonrasib.  

Episode metadata supplied by the publisher feed · Published Jul 24, 2026

Embed this episode

Ready to play

MPR Weekly Dose Podcast #281 — Kalshi Start Clinical Trial Predictions; Positive Results for Retatrutide; Jideytro Approved; Smart Toilet Launches; Daraxonrasib NDA Accepted

0:00 15:03

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 15 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on July 24, 2026.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!